Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 88 | 2024 | 3011 | 15.100 |
Why?
|
Mastectomy | 48 | 2023 | 245 | 14.610 |
Why?
|
Carcinoma, Ductal, Breast | 22 | 2022 | 159 | 7.440 |
Why?
|
Carcinoma, Lobular | 18 | 2019 | 81 | 6.100 |
Why?
|
Mastectomy, Segmental | 18 | 2023 | 101 | 4.140 |
Why?
|
Surgeons | 11 | 2023 | 248 | 3.870 |
Why?
|
Mammaplasty | 10 | 2023 | 109 | 3.130 |
Why?
|
Prophylactic Mastectomy | 8 | 2020 | 13 | 2.930 |
Why?
|
Neoadjuvant Therapy | 8 | 2019 | 377 | 2.680 |
Why?
|
Neoplasm Staging | 25 | 2019 | 2018 | 2.550 |
Why?
|
Time-to-Treatment | 4 | 2024 | 114 | 2.540 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 7 | 2022 | 116 | 2.380 |
Why?
|
Cancer Care Facilities | 4 | 2023 | 29 | 2.130 |
Why?
|
Quality Indicators, Health Care | 5 | 2021 | 146 | 2.080 |
Why?
|
Lymph Node Excision | 10 | 2021 | 220 | 2.020 |
Why?
|
Receptors, Estrogen | 10 | 2022 | 393 | 1.990 |
Why?
|
Female | 91 | 2024 | 46202 | 1.970 |
Why?
|
Surgical Oncology | 4 | 2020 | 27 | 1.960 |
Why?
|
Sentinel Lymph Node Biopsy | 12 | 2021 | 72 | 1.940 |
Why?
|
Middle Aged | 66 | 2024 | 25974 | 1.940 |
Why?
|
Radiation Oncology | 3 | 2021 | 121 | 1.920 |
Why?
|
Databases, Factual | 18 | 2018 | 856 | 1.820 |
Why?
|
Prognosis | 25 | 2020 | 3783 | 1.820 |
Why?
|
Accreditation | 3 | 2019 | 62 | 1.810 |
Why?
|
Practice Guidelines as Topic | 7 | 2019 | 1047 | 1.710 |
Why?
|
Aged | 52 | 2024 | 19165 | 1.670 |
Why?
|
Aged, 80 and over | 34 | 2023 | 6811 | 1.600 |
Why?
|
Guideline Adherence | 4 | 2018 | 230 | 1.600 |
Why?
|
Follow-Up Studies | 21 | 2020 | 3666 | 1.570 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2020 | 1365 | 1.560 |
Why?
|
Humans | 101 | 2024 | 89357 | 1.520 |
Why?
|
Chemotherapy, Adjuvant | 8 | 2019 | 487 | 1.480 |
Why?
|
Radiotherapy, Adjuvant | 9 | 2021 | 296 | 1.480 |
Why?
|
Unilateral Breast Neoplasms | 4 | 2020 | 5 | 1.420 |
Why?
|
Patient Reported Outcome Measures | 5 | 2024 | 192 | 1.420 |
Why?
|
Mastectomy, Subcutaneous | 2 | 2022 | 8 | 1.380 |
Why?
|
Nipples | 6 | 2022 | 37 | 1.350 |
Why?
|
Adult | 47 | 2024 | 26607 | 1.330 |
Why?
|
Thoracic Wall | 2 | 2018 | 25 | 1.240 |
Why?
|
Receptor, ErbB-2 | 5 | 2019 | 246 | 1.220 |
Why?
|
Lymph Nodes | 4 | 2018 | 548 | 1.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 2566 | 1.170 |
Why?
|
United States | 28 | 2024 | 6989 | 1.160 |
Why?
|
Practice Patterns, Physicians' | 5 | 2020 | 601 | 1.130 |
Why?
|
Breast Diseases | 2 | 2022 | 100 | 1.120 |
Why?
|
Decision Support Techniques | 2 | 2019 | 167 | 1.100 |
Why?
|
Neoplasm Invasiveness | 9 | 2020 | 576 | 1.080 |
Why?
|
Ergonomics | 3 | 2022 | 22 | 1.080 |
Why?
|
Breast Neoplasms, Male | 2 | 2023 | 31 | 1.050 |
Why?
|
Combined Modality Therapy | 8 | 2021 | 1719 | 1.050 |
Why?
|
Decision Making | 4 | 2019 | 667 | 1.020 |
Why?
|
Breast | 6 | 2021 | 292 | 1.000 |
Why?
|
Axilla | 11 | 2021 | 104 | 0.980 |
Why?
|
Biomarkers, Tumor | 5 | 2019 | 1549 | 0.980 |
Why?
|
Receptors, Progesterone | 6 | 2019 | 174 | 0.970 |
Why?
|
Neoplasms, Second Primary | 3 | 2017 | 260 | 0.970 |
Why?
|
Survival Rate | 12 | 2018 | 1901 | 0.950 |
Why?
|
Retrospective Studies | 24 | 2024 | 9057 | 0.950 |
Why?
|
Surveys and Questionnaires | 8 | 2023 | 2624 | 0.920 |
Why?
|
Qualitative Research | 2 | 2024 | 296 | 0.890 |
Why?
|
Attitude of Health Personnel | 4 | 2023 | 645 | 0.880 |
Why?
|
Young Adult | 15 | 2024 | 6312 | 0.870 |
Why?
|
Carcinoma | 2 | 2017 | 443 | 0.850 |
Why?
|
Brachytherapy | 2 | 2014 | 121 | 0.850 |
Why?
|
Healthcare Disparities | 3 | 2024 | 420 | 0.810 |
Why?
|
Patient Satisfaction | 5 | 2024 | 461 | 0.810 |
Why?
|
Organ Sparing Treatments | 2 | 2019 | 46 | 0.800 |
Why?
|
Medical Overuse | 2 | 2019 | 36 | 0.790 |
Why?
|
Neoplasm Grading | 10 | 2018 | 374 | 0.760 |
Why?
|
Oncologists | 1 | 2021 | 36 | 0.730 |
Why?
|
Quality of Health Care | 3 | 2018 | 385 | 0.720 |
Why?
|
Lymphatic Metastasis | 7 | 2018 | 502 | 0.660 |
Why?
|
Burnout, Professional | 1 | 2021 | 102 | 0.660 |
Why?
|
Age Factors | 9 | 2018 | 1870 | 0.660 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2017 | 157 | 0.640 |
Why?
|
Stereotaxic Techniques | 1 | 2019 | 80 | 0.640 |
Why?
|
Prophylactic Surgical Procedures | 2 | 2015 | 7 | 0.630 |
Why?
|
Patient Selection | 6 | 2019 | 684 | 0.630 |
Why?
|
Image-Guided Biopsy | 1 | 2019 | 68 | 0.630 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 319 | 0.610 |
Why?
|
Coronavirus Infections | 2 | 2020 | 304 | 0.610 |
Why?
|
Reoperation | 5 | 2015 | 599 | 0.610 |
Why?
|
Patient Care | 1 | 2019 | 102 | 0.600 |
Why?
|
Radiography, Interventional | 1 | 2019 | 154 | 0.600 |
Why?
|
Genes, BRCA2 | 3 | 2016 | 161 | 0.590 |
Why?
|
Patient Transfer | 1 | 2018 | 94 | 0.590 |
Why?
|
Consensus | 2 | 2016 | 356 | 0.590 |
Why?
|
Genes, BRCA1 | 3 | 2016 | 192 | 0.590 |
Why?
|
Hospitals, Low-Volume | 1 | 2017 | 18 | 0.590 |
Why?
|
Patient Acceptance of Health Care | 2 | 2017 | 260 | 0.570 |
Why?
|
Hospitals, High-Volume | 1 | 2017 | 36 | 0.570 |
Why?
|
Radiotherapy, Conformal | 1 | 2017 | 84 | 0.560 |
Why?
|
Patient Preference | 4 | 2019 | 111 | 0.550 |
Why?
|
Logistic Models | 7 | 2017 | 1213 | 0.540 |
Why?
|
Adolescent | 9 | 2024 | 9263 | 0.540 |
Why?
|
Postoperative Complications | 7 | 2016 | 2284 | 0.530 |
Why?
|
Societies, Medical | 2 | 2019 | 575 | 0.520 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 533 | 0.500 |
Why?
|
Pandemics | 6 | 2023 | 773 | 0.500 |
Why?
|
Prospective Studies | 8 | 2022 | 4289 | 0.490 |
Why?
|
Estrogen Receptor alpha | 2 | 2013 | 148 | 0.480 |
Why?
|
Quality of Life | 4 | 2019 | 1668 | 0.470 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 1714 | 0.440 |
Why?
|
Patient Education as Topic | 1 | 2016 | 360 | 0.440 |
Why?
|
Elective Surgical Procedures | 1 | 2014 | 126 | 0.420 |
Why?
|
Receptors, Notch | 2 | 2010 | 123 | 0.410 |
Why?
|
Length of Stay | 3 | 2015 | 736 | 0.410 |
Why?
|
Melanoma | 2 | 2009 | 468 | 0.410 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2013 | 176 | 0.400 |
Why?
|
Skin Neoplasms | 2 | 2009 | 580 | 0.380 |
Why?
|
Workload | 2 | 2022 | 129 | 0.370 |
Why?
|
Operating Rooms | 2 | 2022 | 129 | 0.360 |
Why?
|
Receptor, Notch1 | 2 | 2010 | 94 | 0.360 |
Why?
|
Patient Readmission | 1 | 2014 | 352 | 0.350 |
Why?
|
Registries | 1 | 2014 | 784 | 0.350 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 2008 | 4 | 0.330 |
Why?
|
Patients | 2 | 2023 | 102 | 0.320 |
Why?
|
Socioeconomic Factors | 3 | 2016 | 588 | 0.300 |
Why?
|
Quality Control | 2 | 2019 | 117 | 0.300 |
Why?
|
Breast Implantation | 3 | 2016 | 13 | 0.290 |
Why?
|
Proto-Oncogene Proteins | 2 | 2010 | 665 | 0.290 |
Why?
|
Calcinosis | 1 | 2008 | 230 | 0.280 |
Why?
|
Incidence | 3 | 2023 | 1595 | 0.280 |
Why?
|
Pilot Projects | 3 | 2019 | 871 | 0.270 |
Why?
|
SEER Program | 3 | 2017 | 197 | 0.270 |
Why?
|
Risk Factors | 6 | 2019 | 5499 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2017 | 838 | 0.260 |
Why?
|
Multivariate Analysis | 4 | 2018 | 988 | 0.260 |
Why?
|
Health Care Surveys | 2 | 2018 | 280 | 0.250 |
Why?
|
Risk Assessment | 4 | 2020 | 2303 | 0.250 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 851 | 0.240 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 3448 | 0.240 |
Why?
|
Referral and Consultation | 2 | 2019 | 341 | 0.240 |
Why?
|
Appointments and Schedules | 1 | 2024 | 54 | 0.230 |
Why?
|
Male | 9 | 2024 | 42411 | 0.230 |
Why?
|
Biopsy | 3 | 2014 | 1184 | 0.220 |
Why?
|
Self Concept | 1 | 2023 | 133 | 0.210 |
Why?
|
Time Factors | 5 | 2016 | 5338 | 0.210 |
Why?
|
Radiotherapy Dosage | 2 | 2014 | 470 | 0.210 |
Why?
|
Cohort Studies | 4 | 2018 | 2872 | 0.180 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 1431 | 0.180 |
Why?
|
Betacoronavirus | 2 | 2020 | 261 | 0.180 |
Why?
|
Mammography | 2 | 2017 | 472 | 0.170 |
Why?
|
Personnel Selection | 1 | 2020 | 60 | 0.170 |
Why?
|
Health Resources | 1 | 2020 | 81 | 0.170 |
Why?
|
Minimally Invasive Surgical Procedures | 2 | 2018 | 253 | 0.170 |
Why?
|
Body Image | 1 | 2019 | 78 | 0.170 |
Why?
|
Specialties, Surgical | 1 | 2020 | 66 | 0.170 |
Why?
|
Longitudinal Studies | 2 | 2020 | 1072 | 0.170 |
Why?
|
Triage | 1 | 2020 | 111 | 0.170 |
Why?
|
Fear | 1 | 2019 | 79 | 0.160 |
Why?
|
User-Computer Interface | 1 | 2020 | 187 | 0.160 |
Why?
|
Treatment Outcome | 5 | 2018 | 8241 | 0.160 |
Why?
|
Interviews as Topic | 1 | 2020 | 339 | 0.160 |
Why?
|
Breast Implants | 2 | 2016 | 25 | 0.160 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2022 | 296 | 0.160 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 122 | 0.160 |
Why?
|
Anxiety | 1 | 2021 | 308 | 0.160 |
Why?
|
Neoplasm Micrometastasis | 1 | 2018 | 6 | 0.160 |
Why?
|
Video Recording | 1 | 2019 | 203 | 0.160 |
Why?
|
Databases as Topic | 1 | 2018 | 94 | 0.160 |
Why?
|
Emotions | 1 | 2021 | 349 | 0.150 |
Why?
|
Patient Participation | 1 | 2019 | 224 | 0.150 |
Why?
|
Telemedicine | 1 | 2020 | 188 | 0.140 |
Why?
|
Patient Compliance | 1 | 2018 | 231 | 0.140 |
Why?
|
Choice Behavior | 1 | 2018 | 160 | 0.140 |
Why?
|
Heterozygote | 2 | 2016 | 373 | 0.140 |
Why?
|
Odds Ratio | 1 | 2018 | 683 | 0.140 |
Why?
|
Sleep | 1 | 2021 | 452 | 0.140 |
Why?
|
Ultrasonography, Mammary | 1 | 2017 | 83 | 0.140 |
Why?
|
Disease Management | 1 | 2018 | 329 | 0.130 |
Why?
|
Surgical Wound Infection | 2 | 2015 | 201 | 0.130 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 179 | 0.130 |
Why?
|
Esthetics | 1 | 2016 | 45 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2016 | 63 | 0.130 |
Why?
|
Illinois | 1 | 2017 | 480 | 0.130 |
Why?
|
Molecular Typing | 1 | 2015 | 17 | 0.130 |
Why?
|
Comprehension | 1 | 2016 | 81 | 0.130 |
Why?
|
Europe | 1 | 2016 | 321 | 0.130 |
Why?
|
Pharyngectomy | 1 | 2015 | 8 | 0.130 |
Why?
|
Neoplasms | 2 | 2022 | 3041 | 0.130 |
Why?
|
Remission Induction | 1 | 2017 | 740 | 0.130 |
Why?
|
Population Surveillance | 1 | 2016 | 216 | 0.130 |
Why?
|
Immunohistochemistry | 2 | 2010 | 1799 | 0.120 |
Why?
|
Physicians | 2 | 2019 | 690 | 0.120 |
Why?
|
Counseling | 1 | 2016 | 164 | 0.120 |
Why?
|
Carcinoma in Situ | 1 | 2015 | 53 | 0.120 |
Why?
|
Selection Bias | 1 | 2014 | 37 | 0.120 |
Why?
|
Linear Models | 1 | 2015 | 421 | 0.120 |
Why?
|
Chemoradiotherapy | 1 | 2017 | 309 | 0.120 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 1109 | 0.120 |
Why?
|
Case-Control Studies | 2 | 2018 | 1862 | 0.120 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 981 | 0.110 |
Why?
|
Adipokines | 1 | 2013 | 17 | 0.110 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 461 | 0.110 |
Why?
|
Receptor, Notch4 | 2 | 2010 | 5 | 0.110 |
Why?
|
Insurance, Health | 1 | 2014 | 162 | 0.110 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2015 | 132 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.110 |
Why?
|
Fatty Acids | 1 | 2013 | 134 | 0.110 |
Why?
|
Robotic Surgical Procedures | 1 | 2018 | 306 | 0.100 |
Why?
|
Surgical Flaps | 1 | 2015 | 249 | 0.100 |
Why?
|
Venous Thromboembolism | 1 | 2015 | 159 | 0.100 |
Why?
|
Adipose Tissue | 1 | 2013 | 259 | 0.090 |
Why?
|
Models, Biological | 1 | 2018 | 1765 | 0.090 |
Why?
|
Health Services Accessibility | 1 | 2014 | 428 | 0.090 |
Why?
|
Reproducibility of Results | 1 | 2017 | 2758 | 0.090 |
Why?
|
Serrate-Jagged Proteins | 1 | 2010 | 13 | 0.090 |
Why?
|
Jagged-1 Protein | 1 | 2010 | 13 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 1063 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 1265 | 0.090 |
Why?
|
Calcium-Binding Proteins | 1 | 2010 | 121 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2010 | 181 | 0.080 |
Why?
|
Lung Neoplasms | 1 | 2022 | 2362 | 0.080 |
Why?
|
False Positive Reactions | 1 | 2008 | 223 | 0.080 |
Why?
|
Receptor Cross-Talk | 1 | 2008 | 34 | 0.080 |
Why?
|
Interferon-alpha | 1 | 2009 | 226 | 0.080 |
Why?
|
Hemostatics | 1 | 2008 | 57 | 0.080 |
Why?
|
Quality Improvement | 2 | 2022 | 451 | 0.080 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2008 | 72 | 0.080 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 416 | 0.080 |
Why?
|
Biopsy, Needle | 1 | 2008 | 233 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2015 | 1096 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 360 | 0.070 |
Why?
|
Hyperplasia | 1 | 2008 | 152 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2009 | 160 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2009 | 171 | 0.070 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 179 | 0.070 |
Why?
|
Obesity | 1 | 2013 | 971 | 0.070 |
Why?
|
Analysis of Variance | 1 | 2008 | 899 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2012 | 2017 | 0.070 |
Why?
|
Disease-Free Survival | 2 | 2011 | 1214 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 2015 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2010 | 1224 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 1723 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2013 | 306 | 0.050 |
Why?
|
Mutation | 1 | 2014 | 4143 | 0.050 |
Why?
|
Organizational Innovation | 1 | 2020 | 41 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2013 | 1057 | 0.040 |
Why?
|
Genetic Testing | 1 | 2023 | 537 | 0.040 |
Why?
|
Program Evaluation | 1 | 2020 | 307 | 0.040 |
Why?
|
Fees and Charges | 1 | 2018 | 14 | 0.040 |
Why?
|
Hospital Charges | 1 | 2018 | 29 | 0.040 |
Why?
|
Sentinel Lymph Node | 1 | 2018 | 17 | 0.040 |
Why?
|
Mass Screening | 1 | 2022 | 636 | 0.040 |
Why?
|
Propensity Score | 1 | 2018 | 147 | 0.040 |
Why?
|
Area Under Curve | 1 | 2018 | 337 | 0.040 |
Why?
|
Urologic Surgical Procedures | 1 | 2018 | 147 | 0.030 |
Why?
|
Postoperative Care | 1 | 2017 | 231 | 0.030 |
Why?
|
Tumor Burden | 1 | 2017 | 308 | 0.030 |
Why?
|
Chicago | 1 | 2020 | 1427 | 0.030 |
Why?
|
ROC Curve | 1 | 2018 | 781 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2013 | 1652 | 0.030 |
Why?
|
Prostatectomy | 1 | 2018 | 477 | 0.030 |
Why?
|
Self Report | 1 | 2016 | 297 | 0.030 |
Why?
|
Prosthesis Failure | 1 | 2015 | 116 | 0.030 |
Why?
|
Communication | 1 | 2018 | 460 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2015 | 169 | 0.030 |
Why?
|
Lipase | 1 | 2013 | 21 | 0.030 |
Why?
|
Serpins | 1 | 2013 | 31 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2015 | 344 | 0.030 |
Why?
|
Nerve Growth Factors | 1 | 2013 | 63 | 0.030 |
Why?
|
Risk | 1 | 2015 | 657 | 0.030 |
Why?
|
Leptin | 1 | 2013 | 102 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 625 | 0.030 |
Why?
|
Eye Proteins | 1 | 2013 | 128 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2012 | 66 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2012 | 96 | 0.030 |
Why?
|
Contraindications | 1 | 2012 | 70 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2012 | 354 | 0.020 |
Why?
|
Comorbidity | 1 | 2015 | 949 | 0.020 |
Why?
|
Sepsis | 1 | 2015 | 321 | 0.020 |
Why?
|
Body Mass Index | 1 | 2013 | 773 | 0.020 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2008 | 41 | 0.020 |
Why?
|
Estradiol | 1 | 2008 | 251 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2008 | 470 | 0.020 |
Why?
|
Mice, Nude | 1 | 2008 | 815 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 557 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2008 | 1088 | 0.020 |
Why?
|
Mice | 1 | 2008 | 11761 | 0.010 |
Why?
|
Animals | 1 | 2008 | 27371 | 0.000 |
Why?
|